|By Marketwired .||
|March 3, 2014 06:00 AM EST|
FOSTER CITY, CA -- (Marketwired) -- 03/03/14 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the fourth quarter and full year 2013 on Wednesday, March 12, 2014. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
(Replay available from Wednesday, March 12, 2014, at 12:30 pm ET until 11:59 pm ET on Wednesday, March 19, 2014)
The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone's website at www.sciclone.com. The information provided on the teleconference is accurate only at the time of the conference call, and SciClone will take no responsibility for providing updated information except as required by law.
SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets, including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical partners, SciClone markets multiple branded products in China which are therapeutically differentiated. The Company has successfully in-licensed products with the potential to become future market leaders and to drive the Company's long-term growth. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.
This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.
Dec. 7, 2016 02:30 PM EST Reads: 934
Dec. 7, 2016 02:30 PM EST Reads: 4,300
Dec. 7, 2016 02:24 PM EST Reads: 191
Dec. 7, 2016 02:15 PM EST Reads: 946
Dec. 7, 2016 02:15 PM EST Reads: 2,188
Dec. 7, 2016 02:15 PM EST Reads: 1,106
Dec. 7, 2016 02:15 PM EST Reads: 3,374
Dec. 7, 2016 01:45 PM EST Reads: 1,102
Dec. 7, 2016 01:30 PM EST Reads: 392
Dec. 7, 2016 01:30 PM EST Reads: 2,143
Dec. 7, 2016 01:24 PM EST Reads: 208
Dec. 7, 2016 12:45 PM EST Reads: 1,077
Dec. 7, 2016 12:35 PM EST Reads: 255
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Dec. 7, 2016 12:30 PM EST Reads: 842
Dec. 7, 2016 12:30 PM EST Reads: 619